Open AccessIntravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis
Author(s) -
Waleed Kian,
Melanie Zemel,
Firas Elobra,
Adam A Sharb,
Dina Levitas,
Yarden Assabag,
Farouq Alguayn,
Alexander Yakobson,
Keren Rouvinov,
Lior Fuchs
Publication year - 2021
Publication title -
anti-cancer drugs
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.651
H-Index - 93
eISSN - 1473-5741
pISSN - 0959-4973
DOI - 10.1097/cad.0000000000001162
Subject(s) - toxic epidermal necrolysis , pembrolizumab , medicine , adverse effect , antibody , lung cancer , dermatology , immune system , immunotherapy , immunology
Pembrolizumab is an immune checkpoint inhibitor used in many different cancers. Several immune-related adverse events (irAEs) have been associated with pembrolizumab, including toxic epidermal necrolysis. Here, we are presenting a patient with non-small cell lung cancer that developed toxic epidermal necrolysis 3-days following initiation of pembrolizumab. Following high-dose steroid therapy, intravenous immunoglobulin 2 g/kg was initiated and resulted in complete resolution of all his irAEs. To our knowledge, this is the first reported case of total re-epithelialization and resolution of immune checkpoint inhibitor-induced toxic epidermal necrolysis following the use of intravenous immunoglobulin.